Company intelligence / Profile preview
Aruvant Sciences
New York, New York, United Statesaruvant.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead therapy ARU-1801 (lentiviral gene therapy) for sickle cell disease is in ongoing Phase 1/2 trials, showing durable, clinically meaningful reduction in disease impact and robust fetal hemoglobin induction with only reduced-intensity conditioning; ARU-2801 (AAV gene therapy for hypophosphatasia) is in preclinical studies demonstrating sustained enzyme activity and disease symptom amelioration in models
- Therapeutic areas
- HematologyRare Diseases
- Modalities
- Gene therapyLentiviral gene therapyAdeno-associated virus gene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Partnerships with patient advocacy groups in sickle cell disease and rare disease communities
Beyond the preview
Go deeper on Aruvant Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aruvant Sciences.